LONDON, July 29, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Friday, July 26, 2013, shares of biotech companies ended mostly lower even as the broader market posted gains. The major movers in the industry included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Geron Corporation (NASDAQ: GERN), Incyte Corporation (NASDAQ: INCY), and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). AAAResearchReports.com has released full comprehensive research on ARNA, GERN, INCY, and SPPI. These free technical analyses can be downloaded by signing up at:
http://www.aaaresearchreports.com/register/
Shares of Arena Pharmaceuticals, Inc. fell sharply on Friday, finishing at $6.86, down 2.14% from its previous trading session's closing price. The company's shares oscillated between $6.83 and $7.01. A total of 3.01 million shares were traded, which is below the daily average volume of 5.84 million. Arena's shares have fallen by 10.91% in the last one month as compared to a loss of 0.03% in the S&P 500. A free technical analysis on ARNA available by signing up at:
http://www.AAAResearchReports.com/ARNA072913.pdf
Geron Corporation's stock fell sharply on Friday, extending its losses for the week. The company's shares oscillated between $1.38 and $1.44 before ending the day 4.17% lower at $1.38. A total of 260,089 shares were traded, which is below the daily average volume of 994,053. The company's shares fell by 6.76% last week. Nonetheless, the stock has advanced 21.05% in the last three months, outperforming the S&P 500, which has gained 6.91% during the same period. Register today and access free research on GERN at:
http://www.AAAResearchReports.com/GERN072913.pdf
Shares of Incyte Corporation edged lower on Friday, reversing some of their recent gains. The company's shares oscillated between $22.74 and $23.46 before finishing the session 0.17% lower at $23.34. A total of 553,069 shares were traded, which is below the daily average volume of 1.18 million. Incyte's shares have gained 2.14% in the last three trading sessions and 6.09% in the last one month, outperforming the S&P 500 during the respective periods. Moreover, the stock is currently trading above its 50-day and 200-day moving averages. The free report on INCY can be downloaded by signing up now at:
http://www.AAAResearchReports.com/INCY072913.pdf
Spectrum Pharmaceuticals, Inc.'s stock fluctuated between gains and losses on Friday before finishing the day flat. The company's shares oscillated between $8.26 and $8.50 before closing the day flat at $8.39. A total of 439,651 shares were traded, which is below the daily average volume of 917,988. Spectrum Pharmaceuticals' shares fell by 1.76% last week. In the last one month, however, the stock has outperformed the broader market, gaining 12.47% as compared to an advance of 5.31% in the S&P 500. A free report on SPPI can be accessed by registering at:
http://www.AAAResearchReports.com/SPPI072913.pdf
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
